Introducing Biogelx’s new cell biologist, Africa Galvez Flores.
Biogelx are happy to welcome on board Africa Galvez Flores, who has just joined the Biogelx team as our resident cell biology researcher. Africa will be working on the development of realistic 3D cancer models using Biogelx proprietary peptide hydrogel technology. These models will be used to test the delivery and effectiveness of bio-orthogonal catalytic systems for the treatment of cancer as part of the Theracat Project.
Previously, Africa worked on neurodegeneration research at University College London Institute of Neurology and Columbia University Medical Center in New York, studying molecular aspects of neuronal death in cellular models of Parkinson’s and Alzheimer’s. She holds an MSc Neuroscience from University College London and a BSc Biochemistry from the University of Navarra. Nowadays, she is pursuing a scientific career in industry, focused on the usage of innovative approaches to treat disease.
Africa will be working alongside the rest of the Biogelx team in Biocity, Scotland, and will also be trained on novel cancer therapies in close collaboration with the rest of the Theracat consortium partners. Read more about this fascinating project that we’re just kicking off with Africa, here.
The aim of the THERACAT network is to consolidate Europe as the world leader in novel catalysis-based approach for cancer therapy.